In the News

Connect with us

Stay Informed.
Get the latest news and updates on MSK’s cancer care and research breakthroughs sent straight to your inbox with our e-newsletters.
Newsletter Sign Up
395 News Items found
Cartoon of different-color heads with speaker and thought bubbles above them.
Feature
What You Should Know about Five Common Cancers

Even the most common cancers have aspects that are not fully grasped by the public.
scientific image of mouse lung cancer cells
Lung Cancer Cells’ ‘Memories’ Suggest New Strategy For Improving Treatment

Research from the lab of cancer biologist Tuomas Tammela shows that some lung cancer cells retain a “memory” of the healthy cell where they came from — one that might be exploited to make an emerging type of lung cancer treatment called KRAS inhibition more effective.
Yonina Murciano-Goroff, Jenny Xue, Bob Li, Piro Lito, and Yulei Zhao.
Finding
MSK Researchers Are Learning Why Some Patients Develop Resistance to Targeted Lung Cancer Drug

A paper from MSK researchers reports that resistance to sotorasib, a new targeted drug for lung cancer, can be caused by many different molecular changes.
Dr. Charles Rudin
FDA Grants Full Approval to Lung Cancer Drug Tarlatamab Based on Trial Led by MSK Researcher

The U.S. Food and Drug Administration (FDA) has granted full approval to the drug tarlatamab, a bispecific T cell engager, for small cell lung cancer, based on results from a phase 3 clinical trial led by Dr. Charles Rudin at MSK.
Cancer biologist Andrea Ventura
In the Lab
Disorderly DNA: Researchers Simulate a Common Cause of Lung Cancer

MSK scientists have created a mouse model that replicates a subtype of non-small cell lung cancer caused by a chromosomal rearrangement.
African-American surgeon in scrubs and mask leaning over patient in OR.
2021 in Review: 10 Important Clinical Advances in Cancer at MSK

Learn about some of the most important clinical advances made at MSK in 2021.
Meryl Jacobs poses with her husband and grandkids
FDA Approves Zenocutuzumab for Pancreatic and Lung Cancers With NRG1 Fusions 

The FDA has granted accelerated approval to zenocutuzumab for treating patients with advanced pancreatic cancer or non-small cell lung cancer with an alteration called an NRG1 gene fusion, based on a phase 2 clinical trial led by an MSK investigator.
David Jones
Lung Health in the Time of COVID-19

MSK experts shared their insights on lung cancer, screening and general lung health in an Information Session for patients, caregivers and those at increased risk for the disease.
detail shot of a scientist pipetting in a lab
MSK Research Highlights, January 20, 2023

New research from MSK explores novel predictors of immunotherapy effectiveness against lung cancer; identifies how a high-fat diet hinders intestinal damage repair; reports findings from a clinical trial for people with androgen receptor-positive salivary gland cancer; and aims to understand the impact of tumor mutational burden on patients with locally advanced non-small cell lung cancer.
Cyclotron engineer and nuclear pharmacist
In the Lab
New Technology May Improve Treatment of Deadly Lung and Prostate Cancers

Learn how a new technology could improve detection and treatment of certain aggressive lung and prostate cancers.